Explanipedia

Supplementary Figure 12 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Börje S. Andersson, Regina Mendrzyk, Katrin Aslan, Fabian Richter , et al. · 2025

Supplementary Figure 12

Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Arun Satelli , et al. · 2025

Supplemental Figure 1

Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Claudia Wagner, Katrin Aslan , et al. · 2025

Supplemental Figure 7

Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Börje S. Andersson, Amir Alpert, Claudia Wagner, Katrin Aslan , et al. · 2025

Supplemental Figure 8

Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Kerstin Guenther, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Katrin Aslan , et al. · 2025

Supplemental Figure 2

Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert , et al. · 2025

Supplemental Figure 3

Supplementary Figure 11 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert , et al. · 2025

Supplementary Figure 11

Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Börje S. Andersson, Amir Alpert, Claudia Wagner, Arun Satelli, Fabian Richter , et al. · 2025

Supplemental Figure 4

Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert , et al. · 2025

Supplemental Figure 10

Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open

Apostolia M. Tsimberidou, Kerstin Guenther, Börje S. Andersson, Amir Alpert, Katrin Aslan , et al. · 2025

Supplemental Figure 6

Curricular Self‐management for patients on ventricular assist device support decreases depression: A multicenter randomized controlled trial Open

Christiane Kugler, Hannah Spielmann, Fabian Richter, Volker Lauenroth, Sandra Semmig‐Könze , et al. · 2024

Background Utilization of ventricular assist device (VAD) support in patients with end‐stage heart failure is well advanced. Recent studies emphasize the need to develop and evaluate evidence‐based psychosocial support interventions for pa…

Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer Open